Trials / Completed
CompletedNCT03873857
A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation
Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 71 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in the Russian Federation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | tablet;oral |
Timeline
- Start date
- 2019-02-25
- Primary completion
- 2022-09-12
- Completion
- 2022-09-12
- First posted
- 2019-03-14
- Last updated
- 2023-09-01
Locations
20 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT03873857. Inclusion in this directory is not an endorsement.